Please use this identifier to cite or link to this item:
Title: Third dose of BNT162b2 improves immune response in liver transplant recipients to ancestral strain but not Omicron BA.1 and XBB
Authors: Chang, Zi Wei
Goh, Yun Shan
Rouers, Angeline
Fong, Siew-Wai
Tay, Matthew Zirui
Chavatte, Jean-Marc
Hor, Pei Xiang
Loh, Chiew Yee
Huang, Yuling
Tan, Yong Jie
Neo, Vanessa
Kam, Isaac Kai Jie
Yeo, Nicholas Kim-Wah
Tan, Eunice X.
Huang, Daniel
Wang, Bei
Siti Nazihah Mohd Salleh
Ngoh, Eve Zi Xian
Wang, Cheng-I
Leo, Yee-Sin
Lin, Raymond Tzer Pin
Lye, David C.
Young, Barnaby Edward
Muthiah, Mark
Ng, Lisa F. P.
Rénia, Laurent
Keywords: Science::Medicine
Issue Date: 2023
Source: Chang, Z. W., Goh, Y. S., Rouers, A., Fong, S., Tay, M. Z., Chavatte, J., Hor, P. X., Loh, C. Y., Huang, Y., Tan, Y. J., Neo, V., Kam, I. K. J., Yeo, N. K., Tan, E. X., Huang, D., Wang, B., Siti Nazihah Mohd Salleh, Ngoh, E. Z. X., Wang, C., ...Rénia, L. (2023). Third dose of BNT162b2 improves immune response in liver transplant recipients to ancestral strain but not Omicron BA.1 and XBB. Frontiers in Immunology, 14, 1206016-.
Project: ACCL/19-GAP064-R20H-H 
SUJ #022388-00001 
Journal: Frontiers in Immunology 
Abstract: Vaccine immunogenicity in transplant recipients can be impacted by the immunosuppressive (IS) regimens they receive. While BNT162b2 vaccination has been shown to induce an immune response in liver transplant recipients (LTRs), it remains unclear how different IS regimens may affect vaccine immunogenicity after a third BNT162b2 dose in LTRs, which is especially important given the emergence of the Omicron sublineages of SARS-CoV-2. A total of 95 LTRs receiving single and multiple IS regimens were recruited and offered three doses of BNT162b2 during the study period. Blood samples were collected on days 0, 90, and 180 after the first BNT162b2 dose. At each time point, levels of anti-spike antibodies, their neutralizing activity, and specific memory B and T cell responses were assessed. LTRs receiving single IS regimens showed an absence of poor immunogenicity, while LTRs receiving multiple IS regimens showed lower levels of spike-specific antibodies and immunological memory compared to vaccinated healthy controls after two doses of BNT162b2. With a third dose of BNT162b2, spike-specific humoral, memory B, and T cell responses in LTR significantly improved against the ancestral strain of SARS-CoV-2 and were comparable to those seen in healthy controls who received only two doses of BNT162b2. However, LTRs receiving multiple IS regimens still showed poor antibody responses against Omicron sublineages BA.1 and XBB. A third dose of BNT162b2 may be beneficial in boosting antibody, memory B, and T cell responses in LTRs receiving multiple IS regimens, especially against the ancestral Wuhan strain of SARS-CoV-2. However, due to the continued vulnerability of LTRs to presently circulating Omicron variants, antiviral treatments such as medications need to be considered to prevent severe COVID-19 in these individuals.
ISSN: 1664-3224
DOI: 10.3389/fimmu.2023.1206016
Schools: Lee Kong Chian School of Medicine (LKCMedicine) 
School of Biological Sciences 
Organisations: National Centre for Infectious Diseases 
Tan Tock Seng Hospital 
Infectious Diseases Labs, A*STAR 
National University of Singapore 
Rights: © 2023 Chang, Goh, Rouers, Fong, Tay, Chavatte, Hor, Loh, Huang, Tan, Neo, Kam, Yeo, Tan, Huang, Wang, Salleh, Ngoh, Wang, Leo, Lin, Lye, Young, Muthiah, Ng, Renia and COVID-19 Study Group. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:LKCMedicine Journal Articles

Files in This Item:
File Description SizeFormat 
fimmu-14-1206016.pdf2.14 MBAdobe PDFThumbnail

Page view(s)

Updated on Jul 18, 2024


Updated on Jul 18, 2024

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.